Drugs / [177Lu]Lu-NNS309
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06562192 | Oct 2024 → Jan 2031 expected | colorectal cancer, invasive ductal and lobular carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma +1 | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-NNS309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06562192 ↗ |